What is the CVSS score of CVE-2023-38955?

CVE-2023-38955 has a CVSS 3.1 base score of 7.5 (High). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N. EPSS exploitation probability: 0.5%.

Bioaccess Ivs CVE-2023-38955

HIGH

Exposure of Resource to Wrong Sphere (CWE-668)

2023-08-03 cve@mitre.org

Information Disclosure Bioaccess Ivs

7.5

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

7.5 HIGH

AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Attack Vector

Network

Attack Complexity

Low

Privileges Required

None

User Interaction

None

Scope

Unchanged

Confidentiality

High

Integrity

None

Availability

None

Lifecycle Timeline

CVE Published

Aug 03, 2023 - 02:15 nvd

HIGH 7.5

DescriptionNVD

ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices, including their IP addresses and device names.

AnalysisAI

ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices, including their IP addresses and device names. Rated high severity (CVSS 7.5), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as Exposure of Resource to Wrong Sphere (CWE-668), which allows attackers to access resources from an unintended security context. ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices, including their IP addresses and device names. Affected products include: Zkteco Bioaccess Ivs.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Implement proper access controls, validate resource access permissions, use security boundaries.